סימבקסון 40

Država: Izrael

Jezik: hebrejščina

Source: Ministry of Health

Kupite ga zdaj

Navodilo za uporabo Navodilo za uporabo (PIL)
06-07-2021

Aktivna sestavina:

SIMVASTATIN

Dostopno od:

DEXCEL PHARMA TECHNOLOGIES LTD

Koda artikla:

C10AA01

Farmacevtska oblika:

קפליות

Sestava:

SIMVASTATIN 40 MG

Pot uporabe:

פומי

Tip zastaranja:

מרשם נדרש

Izdeluje:

DEXCEL LTD, ISRAEL

Terapevtska skupina:

SIMVASTATIN

Terapevtsko območje:

SIMVASTATIN

Terapevtske indikacije:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hype

Povzetek izdelek:

Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin

Datum dovoljenje:

2020-04-30

Dokumenti v drugih jezikih

Navodilo za uporabo Navodilo za uporabo angleščina 20-01-2021
Javno poročilo o oceni Javno poročilo o oceni angleščina 18-08-2016
Navodilo za uporabo Navodilo za uporabo arabščina 20-01-2021

Opozorila o iskanju, povezana s tem izdelkom